Navigation Links
Castle Creek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for Diacerein 1% Ointment in Treatment of Epidermolysis Bullosa Simplex
Date:3/6/2017

PARSIPPANY, N.J., March 6, 2017 /PRNewswire/ -- Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with dermatologic and head/neck orphan diseases and underserved conditions, today announced that results from a placebo-controlled clinical trial for topical diacerein 1% in the treatment of epidermolysis bullosa simplex (EBS) were presented in a late-breaker session at the American Academy of Dermatology Annual Meeting in Orlando. Results were presented by Professor Johann Bauer, MD, MBA, HCM, head of the University Clinic for Dermatology at the SALK/Paracelsus Medical University and principal investigator in the trial. 

The multicenter, randomized, double-blind, placebo-controlled phase 2 trial included 17 patients with EBS who were treated for four weeks followed by three-month follow-up and subsequent cross-over in year two. Results, which were previously reported, showed a 60 percent reduction in blistering among patients treated with diacerein 1% versus a 15 percent reduction in the placebo group at four weeks. At three months, 67 percent of patients in the placebo group returned to baseline blistering levels, versus 12.5 percent of patients in the diacerein 1% treatment group. Topical diacerein 1% was well tolerated with no treatment-related adverse events reported.

"With no treatment options available, management of EBS remains a significant area of unmet need in healthcare. These results represent a historic advance in research related to EBS indicating the potential to bring patients a safe and effective treatment option in the years ahead," said Dr. Bauer. "Importantly, these results also show the potential for diacerein 1% to offer long-term benefits in patients experiencing blistering associated with EBS."

EBS is the most common form of epidermolysis bullosa, a rare dermatologic condition where patients (many of them children) have a genetic defect that compromises the structural integrity of their skin, making it particularly fragile and prone to blistering over their entire bodies. Severe cases of EBS involve widespread blistering that can lead to infections, dehydration, and other medical problems. CCP-020 (diacerein 1% ointment) is an investigational therapy in development at Castle Creek Pharmaceuticals for the treatment of EBS. It is a potentially disease-modifying therapy that blocks an important inflammatory signaling pathway in EBS.

"The results of this important clinical trial for diacerein 1% are another milestone in our plan to identify and advance a pipeline of promising therapies to treat rare and orphan diseases in dermatologic and head/neck indications," said Greg Licholai, MD, president and chief scientific officer at Castle Creek Pharmaceuticals. "We look forward to advancing this development program through the final stages of regulatory review as rapidly as possible in our effort to bring a safe and effective treatment option to patients affected by EBS around the world."

About Castle Creek Pharmaceuticals 
Castle Creek Pharmaceuticals (CCP) is a privately held biopharmaceutical company with a robust and diversified pipeline of late-stage products. The company business strategy is based on a demonstrated ability to identify and advance therapies backed by strong science with the potential to represent significant advances in the treatment of rare and debilitating dermatologic and head and neck conditions. For more information, please visit www.castlecreekpharma.com.

Media contact:

Adam Daley 
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/castle-creek-pharmaceuticals-announces-presentation-of-phase-2-clinical-data-for-diacerein-1-ointment-in-treatment-of-epidermolysis-bullosa-simplex-300417864.html


'/>"/>
SOURCE Castle Creek Pharmaceuticals
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Simultaneous Applications Submitted to FDA and EMA for Siltuximab for the Treatment of Multicentric Castleman Disease, a Rare Blood Disorder
2. Siltuximab Pivotal Trial Data Show Efficacy for Treatment of Patients with Multicentric Castlemans Disease
3. Maurice Preter, neuropsychiatrist and founder of elite medical concierge, selected Castle Connolly Top Doctor
4. TWi Biotechnology Inc. Announces Development and Commercialization Agreement and Collaboration with Castle Creek Pharmaceuticals, LLC
5. Creekridge Capital Adds Revolving Credit Specialist
6. Creekridge Capital Expands Healthcare Sales Team
7. Creekridge Capital Launches Vendor Sales Training Program
8. Creekridge Capital Grows Healthcare Sales Team
9. Creekridge Breaks Monthly and Quarterly Volume Records
10. Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application
11. Creekridge Capital Signs Several New Vendor Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... July 17, 2019 , ... ... the MDA for their fourth annual national “Be Their Muscle” philanthropic event, and ... the lives of kids and adults with muscular dystrophy, ALS and related neuromuscular ...
(Date:7/17/2019)... Texas (PRWEB) , ... July 17, 2019 , ... ... management profession, recently tapped First American as its payment processor of record. ... operators who use the Halcyon business management platform can now also accept and ...
(Date:7/17/2019)... ... July 17, 2019 , ... Gwinnett Family Dental ... and trusted provider of complete dental care, including general and preventative care as well ... with a large team of extensively trained dentists, Dr. Kell Gallaher, Dr. Jon Klevansky, ...
Breaking Medicine Technology:
(Date:7/18/2019)... ... July 18, 2019 , ... For the fourth ... Atlanta, Magazine’s list of “Top Doctors” issue. Deutsch is a double-board-certified plastic and, ... With specialized training from MD Anderson Cancer Center and Albert Einstein, Montefiore Medical ...
(Date:7/17/2019)... VEGAS (PRWEB) , ... July 17, 2019 , ... ... innovative thought leader offering fresh, insightful, honest perspectives on today’s issues affecting humanity ... from Noon, 12 p.m. PST on Saturday, July 20, 2019. , Guruji ...
(Date:7/17/2019)... ... July 17, 2019 , ... It took just several small incisions ... MD, to relieve pressure on the nerves under Amber Walck’s scalp, and suddenly her ... turned 30 last year, her debilitating headaches began without warning. About 39 million ...
(Date:7/17/2019)... , ... July 17, 2019 , ... A new study ... Journal of the American Medical Association (JAMA), shows for the first time that ... in the state. Sepsis is the body’s extreme response to infection. It kills more ...
(Date:7/13/2019)... ... 14, 2019 , ... Dr. Rupa Jolly, dentist and wife of Dr. Tarun ... of Most Influential New Orleanians in 2019. She joins more than 20 other locals ... made an impact on the New Orleans community. , Combining their backgrounds in science ...
Breaking Medicine News(10 mins):